Business Wire - Multimedia Available: FDA Approves SINGULAIR For Seasonal Allergic Rhinitis
Health & Pharmaceutical Writers
ADVISORY…for Thursday (Jan. 3)
NOTE TO EDITORS: Multimedia Assets Available With This Story
Include Photos, Text News Releases
–(BUSINESS WIRE)
Merck & Co. Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the leukotriene blocker SINGULAIR(R) (montelukast sodium) for the relief of symptoms of seasonal allergic rhinitis (also known as hay fever). A convenient once-a-day tablet, SINGULAIR helps relieve a broad range of seasonal allergy symptoms for 24 hours. SINGULAIR is available to treat seasonal allergic rhinitis in adults and children as young as 2 years of age.
Related Results
Popular prescription drugs
Gilead Names John W. Madigan to Board and Merck Announces US Label Change for…
Positive new data for Merck & Co’s Singulair.
For allergic rhinitis, two drugs found equivalent.(Pulmonary Medicine)(Drug o…
Drug patent expiration list. (Rx/Generic Drugs).(Brief Article)
You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?8141
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics, and photos.
If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.
COPYRIGHT 2003 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
